Investment Thesis
Adial Pharmaceuticals is a pre-revenue or non-operating pharmaceutical company with severe fundamental weaknesses, including $8.0M net losses, negative operating cash flow of $6.5M, and zero revenue generation. The company is essentially burning through its limited cash reserves ($5.9M) while consuming approximately $6.6M in annual free cash flow, indicating a runway of less than one year without additional financing or revenue inflection.
ADIL Strengths
- Strong liquidity position with current ratio of 4.42x and $5.9M in cash
- Zero long-term debt provides clean balance sheet structure
- Low liability burden at $1.4M relative to $6.7M in total assets
ADIL Risks
- No revenue generation indicates lack of commercialized products or active business operations
- Operating losses of $7.8M with negative operating cash flow of $6.5M demonstrates unsustainable cash burn
- Cash runway of approximately 11 months at current burn rate creates critical liquidity risk without additional financing or revenue generation
- Severely negative ROE (-151.2%) and ROA (-119.5%) indicate capital destruction
- Interest coverage of -76.0x reflects inability to cover any debt service from operations
- Zero insider Form 4 filings in last 90 days suggests lack of insider confidence or activity
Key Metrics to Watch
- Revenue generation and product commercialization progress
- Monthly cash burn rate and runway to profitability or additional financing
- Operating cash flow trajectory and path to positive operations
- Pipeline advancement and clinical trial progress for pharmaceutical candidates
ADIL Financial Metrics
ADIL Profitability Ratios
ADIL Balance Sheet & Liquidity
ADIL 5-Year Financial Trend
5-Year Trend Summary: ADIAL PHARMACEUTICALS, INC.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-68.01 indicates the company is currently unprofitable.
ADIL Growth Metrics (YoY)
ADIL Capital Allocation
ADIL SEC Filings
Access official SEC EDGAR filings for ADIAL PHARMACEUTICALS, INC. (CIK: 0001513525)